Skip to main content
. 2016 Apr 14;6:24090. doi: 10.1038/srep24090

Figure 5. HIV-1 protease inhibitors block Akt activation in rNef-treated PBLs in vitro and ex vivo in PBLs isolated from cART-treated patients.

Figure 5

(A), HIV protease inhibitors, but not RTIs, inhibit pAkt(Ser473) activation in a dose dependent manner in PBLs treated with rNef as determined by western blot. Five million PBLs were treated with rNef (100 ng/ml) for 30 min. Expression of pAkt(Ser473), total Akt and β-actin was determined by western blotting (n = 8). (B), Decreased Akt activation in PBLs from PI-treated patients compared to RTI-treated and cART naive patients as measured by flow cytometric analysis. Mean values ± s.d. (n = 5). (C), Decreased Akt activation in PBLs from PI-treated patients compared to RTI-treated and cART naive patients as measured by western-blotting.